{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:08:25Z","timestamp":1788797305604,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Extracellular vesicle (EV)-mediated transfer of microRNAs has emerged as a critical mechanism driving tumor progression, yet its functional relevance in nasopharyngeal carcinoma (NPC) remains poorly defined. This study sought to elucidate the functional role and molecular mechanism of EV-associated miR-7111-3p in NPC progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>miR-7111-3p expression was measured in serum samples from NPC patients and in NPC cell lines. Functional effects were evaluated through gain- and loss-of-function assays in vitro and in xenograft models. Direct targeting of amyloid precursor protein (APP) by miR-7111-3p was validated using dual-luciferase reporter assays. EV-mediated transfer was assessed by EV isolation, characterization, and co-culture experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>miR-7111-3p was significantly downregulated in NPC serum and cell lines. Its overexpression markedly suppressed NPC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT), whereas its knockdown exerted the opposite effects. APP was identified as a direct target of miR-7111-3p, and APP overexpression reversed the inhibitory effects induced by miR-7111-3p. EVs derived from miR-7111-3p-deficient NPC cells promoted APP expression, proliferation and migration in recipient NP69 cells, whereas inhibition of EV secretion attenuated these effects. In vivo, miR-7111-3p overexpression reduced xenograft tumor growth and downregulated APP expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings identify a novel EV-miR-7111-3p-APP signaling axis that regulates EMT, malignant phenotypes and tumor growth in NPC, highlighting its potential as a therapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08674-1","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:28:45Z","timestamp":1785414525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EV-transferred miR-7111-3p inhibits malignant phenotypes and tumor growth in nasopharyngeal carcinoma via targeting APP-regulated epithelial-mesenchymal transition"],"prefix":"10.1186","volume":"24","author":[{"given":"Hejing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziman","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huining","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"4","key":"8674_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021;32(4):452\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.007.","journal-title":"Ann Oncol"},{"issue":"3","key":"8674_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"8674_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2147\/OTT.S188148","volume":"12","author":"F Perri","year":"2019","unstructured":"Perri F, Della Vittoria Scarpati G, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives. Onco Targets Ther. 2019;12:1583\u201391. https:\/\/doi.org\/10.2147\/OTT.S188148. Published 2019 Feb 26.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"8674_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39(7):840\u201359. https:\/\/doi.org\/10.1200\/JCO.20.03237.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8674_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41392-022-01132-6","volume":"7","author":"GG Jinesh","year":"2022","unstructured":"Jinesh GG, Brohl AS. Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis. Signal Transduct Target Ther. 2022;7(1):296. https:\/\/doi.org\/10.1038\/s41392-022-01132-6. Published 2022 Aug 23.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"8674_CR6","doi-asserted-by":"publisher","first-page":"100879","DOI":"10.1016\/j.tranon.2020.100879","volume":"14","author":"A Katoch","year":"2021","unstructured":"Katoch A, Jamwal VL, Faheem MM, et al. Overlapping targets exist between the Par-4 and miR-200c axis which regulate EMT and proliferation of pancreatic cancer cells. Transl Oncol. 2021;14(1):100879. https:\/\/doi.org\/10.1016\/j.tranon.2020.100879.","journal-title":"Transl Oncol"},{"key":"8674_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev.pathol.4.110807.092222","volume":"4","author":"YS Lee","year":"2009","unstructured":"Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199\u2013227. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092222.","journal-title":"Annu Rev Pathol"},{"key":"8674_CR8","doi-asserted-by":"publisher","unstructured":"Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: a promising therapeutic target in cancer. Int J Mol Sci. 2022;23(19):11502. Published 2022 Sep 29. https:\/\/doi.org\/10.3390\/ijms231911502.","DOI":"10.3390\/ijms231911502"},{"key":"8674_CR9","doi-asserted-by":"publisher","first-page":"108122","DOI":"10.1016\/j.pharmthera.2022.108122","volume":"235","author":"Y Cho","year":"2022","unstructured":"Cho Y, Bae HG, Okun E, Arumugam TV, Jo DG. Physiology and pharmacology of amyloid precursor protein. Pharmacol Ther. 2022;235:108122. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108122.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"8674_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3892\/mmr.2019.10293","volume":"20","author":"J Xu","year":"2019","unstructured":"Xu J, Ying Y, Xiong G, Lai L, Wang Q, Yang Y. Amyloid \u03b2 precursor protein silencing attenuates epithelial\u2013mesenchymal transition of nasopharyngeal carcinoma cells via inhibition of the MAPK pathway. Mol Med Rep. 2019;20(1):409\u201316. https:\/\/doi.org\/10.3892\/mmr.2019.10293.","journal-title":"Mol Med Rep"},{"issue":"1","key":"8674_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3892\/ijmm.2019.4404","volume":"45","author":"X Wu","year":"2020","unstructured":"Wu X, Chen S, Lu C. Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway. Int J Mol Med. 2020;45(1):162\u201374. https:\/\/doi.org\/10.3892\/ijmm.2019.4404.","journal-title":"Int J Mol Med"},{"issue":"2","key":"8674_CR12","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. https:\/\/doi.org\/10.1002\/jev2.12404.","journal-title":"J Extracell Vesicles"},{"issue":"Pt 1","key":"8674_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcancer.2022.01.003","volume":"86","author":"T Eguchi","year":"2022","unstructured":"Eguchi T, Sheta M, Fujii M, Calderwood SK. Cancer extracellular vesicles, tumoroid models, and tumor microenvironment. Semin Cancer Biol. 2022;86(Pt 1):112\u201326. https:\/\/doi.org\/10.1016\/j.semcancer.2022.01.003.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"8674_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12943-024-02116-6","volume":"23","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yu D, Ji C, et al. Exosomal miR-4745-5p\/3911 from N2-polarized tumor-associated neutrophils promotes gastric cancer metastasis by regulating SLIT2. Mol Cancer. 2024;23(1):198. https:\/\/doi.org\/10.1186\/s12943-024-02116-6. Published 2024 Sep 13.","journal-title":"Mol Cancer"},{"key":"8674_CR15","doi-asserted-by":"publisher","first-page":"126907","DOI":"10.1016\/j.talanta.2024.126907","volume":"282","author":"P Lu","year":"2025","unstructured":"Lu P, Yang L, Chen W, Li K, Chen X, Qu S. Four-dimensional trapped ion mobility spectrometry proteomics reveals circulating extracellular vesicles encapsulated drivers of nasopharyngeal carcinoma distant dissemination. Talanta. 2025;282:126907. https:\/\/doi.org\/10.1016\/j.talanta.2024.126907.","journal-title":"Talanta"},{"issue":"1\u20132","key":"8674_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10495-022-01788-z","volume":"28","author":"Z Qin","year":"2023","unstructured":"Qin Z, Wang X, Zhou Y, Zheng J, Li H, Li L. Upregulation of miR-29b-3p alleviates coronary microembolization-induced myocardial injury via regulating BMF and GSK-3\u03b2. Apoptosis. 2023;28(1\u20132):210\u201321. https:\/\/doi.org\/10.1007\/s10495-022-01788-z.","journal-title":"Apoptosis"},{"key":"8674_CR17","doi-asserted-by":"publisher","unstructured":"Dong N, Qi W, Wu L et al. LINC00606 promotes glioblastoma progression through sponge miR-486-3p and interaction with ATP11B. J Exp Clin Cancer Res. 2024;43(1):139. Published 2024 May 9. https:\/\/doi.org\/10.1186\/s13046-024-03058-z.","DOI":"10.1186\/s13046-024-03058-z"},{"issue":"7","key":"8674_CR18","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1080\/15548627.2020.1781368","volume":"17","author":"Q Zhu","year":"2021","unstructured":"Zhu Q, Zhang Q, Gu M, et al. MIR106A-5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma. Autophagy. 2021;17(7):1667\u201383. https:\/\/doi.org\/10.1080\/15548627.2020.1781368.","journal-title":"Autophagy"},{"issue":"1","key":"8674_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12967-019-02203-z","volume":"18","author":"FZ Wan","year":"2020","unstructured":"Wan FZ, Chen KH, Sun YC, et al. Exosomes overexpressing miR-34c inhibit malignant behavior and reverse the radioresistance of nasopharyngeal carcinoma. J Transl Med. 2020;18(1):12. Published 2020 Jan 8https:\/\/doi.org\/10.1186\/s12967-019-02203-z.","journal-title":"J Transl Med"},{"key":"8674_CR20","doi-asserted-by":"publisher","first-page":"108118","DOI":"10.1016\/j.pharmthera.2022.108118","volume":"234","author":"PC Shih","year":"2022","unstructured":"Shih PC. The role of the STAT3 signaling transduction pathways in radioresistance. Pharmacol Ther. 2022;234:108118. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108118.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"8674_CR21","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.7150\/ijbs.69934","volume":"18","author":"J Jiang","year":"2022","unstructured":"Jiang J, Tang Q, Gong J, et al. Radiosensitizer EXO-miR-197-3p Inhibits Nasopharyngeal Carcinoma Progression and Radioresistance by Regulating the AKT\/mTOR Axis and HSPA5-mediated Autophagy. Int J Biol Sci. 2022;18(5):1878\u201395. https:\/\/doi.org\/10.7150\/ijbs.69934. Published 2022 Feb 21.","journal-title":"Int J Biol Sci"},{"issue":"17","key":"8674_CR22","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1038\/onc.2014.341","volume":"34","author":"LM Cai","year":"2015","unstructured":"Cai LM, Lyu XM, Luo WR, et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene. 2015;34(17):2156\u201366. https:\/\/doi.org\/10.1038\/onc.2014.341.","journal-title":"Oncogene"},{"issue":"3","key":"8674_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cac2.12138","volume":"41","author":"G Pan","year":"2021","unstructured":"Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun (Lond). 2021;41(3):199\u2013217. https:\/\/doi.org\/10.1002\/cac2.12138.","journal-title":"Cancer Commun (Lond)"},{"key":"8674_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12935-019-0915-x","volume":"19","author":"Y Lv","year":"2019","unstructured":"Lv Y, Yang H, Ma X, Wu G. Strand-specific miR-28-3p and miR-28-5p have differential effects on nasopharyngeal cancer cells proliferation, apoptosis, migration and invasion. Cancer Cell Int. 2019;19:187. https:\/\/doi.org\/10.1186\/s12935-019-0915-x. Published 2019 Jul 19.","journal-title":"Cancer Cell Int"},{"key":"8674_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.biopha.2018.06.115","volume":"106","author":"G Huang","year":"2018","unstructured":"Huang G, Du MY, Zhu H, et al. MiRNA-34a reversed TGF-\u03b2-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells. Biomed Pharmacother. 2018;106:217\u201324. https:\/\/doi.org\/10.1016\/j.biopha.2018.06.115.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"8674_CR26","doi-asserted-by":"publisher","first-page":"e20210313","DOI":"10.1084\/jem.20210313","volume":"218","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhang CM, Prokopenko D, et al. An APP ectodomain mutation outside of the A\u03b2 domain promotes A\u03b2 production in vitro and deposition in vivo. J Exp Med. 2021;218(6):e20210313. https:\/\/doi.org\/10.1084\/jem.20210313.","journal-title":"J Exp Med"},{"issue":"11","key":"8674_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/cas.12239","volume":"104","author":"K Takagi","year":"2013","unstructured":"Takagi K, Ito S, Miyazaki T, et al. Amyloid precursor protein in human breast cancer: an androgen-induced gene associated with cell proliferation. Cancer Sci. 2013;104(11):1532\u20138. https:\/\/doi.org\/10.1111\/cas.12239.","journal-title":"Cancer Sci"},{"key":"8674_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ebiom.2018.11.012","volume":"38","author":"JYS Tsang","year":"2018","unstructured":"Tsang JYS, Lee MA, Chan TH, et al. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer. EBioMedicine. 2018;38:89\u201399. https:\/\/doi.org\/10.1016\/j.ebiom.2018.11.012.","journal-title":"EBioMedicine"},{"issue":"1","key":"8674_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/0008-5472.CAN-08-3633","volume":"69","author":"K Takayama","year":"2009","unstructured":"Takayama K, Tsutsumi S, Suzuki T, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res. 2009;69(1):137\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3633.","journal-title":"Cancer Res"},{"issue":"13","key":"8674_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.14715\/cmb\/2023.69.13.26","volume":"69","author":"Y Hong","year":"2023","unstructured":"Hong Y, Wei Z, Wang Y. Proteolytic cleavage of amyloid precursor protein by ADAM10 promotes proliferation and migration via activating MAPKs pathway in tongue squamous cell carcinoma in vitro. Cell Mol Biol (Noisy-le-grand). 2023;69(13):167\u201373. https:\/\/doi.org\/10.14715\/cmb\/2023.69.13.26. Published 2023 Dec 10.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"6478","key":"8674_CR31","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. https:\/\/doi.org\/10.1126\/science.aau6977.","journal-title":"Science"},{"issue":"8","key":"8674_CR32","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610\u201326. https:\/\/doi.org\/10.1016\/j.cell.2023.03.010.","journal-title":"Cell"},{"key":"8674_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2020.03.004","volume":"478","author":"X Wu","year":"2020","unstructured":"Wu X, Zhou Z, Xu S, et al. Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. Cancer Lett. 2020;478:93\u2013106. https:\/\/doi.org\/10.1016\/j.canlet.2020.03.004.","journal-title":"Cancer Lett"},{"issue":"13","key":"8674_CR34","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1080\/15384101.2023.2216508","volume":"22","author":"Q Zhong","year":"2023","unstructured":"Zhong Q, Nie Q, Wu R, Huang Y. Exosomal miR-18a-5p promotes EMT and metastasis of NPC cells via targeting BTG3 and activating the Wnt\/\u03b2-catenin signaling pathway. Cell Cycle. 2023;22(13):1544\u201362. https:\/\/doi.org\/10.1080\/15384101.2023.2216508.","journal-title":"Cell Cycle"},{"issue":"1","key":"8674_CR35","doi-asserted-by":"publisher","first-page":"101343","DOI":"10.1016\/j.bjorl.2023.101343","volume":"90","author":"XJ Zhou","year":"2024","unstructured":"Zhou XJ, Xu HM, Huang GS, Lin BR. Nasopharyngeal carcinoma derived exosomes regulate the proliferation and migration of nasopharyngeal carcinoma cells by mediating the miR-99a-5p BAZ2A axis. Braz J Otorhinolaryngol. 2024;90(1):101343. https:\/\/doi.org\/10.1016\/j.bjorl.2023.101343.","journal-title":"Braz J Otorhinolaryngol"},{"key":"8674_CR36","doi-asserted-by":"publisher","unstructured":"Raza A, Khan AQ, Inchakalody VP et al. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J Exp Clin Cancer Res. 2022;41(1):99. Published 2022 Mar 15. https:\/\/doi.org\/10.1186\/s13046-022-02318-0.","DOI":"10.1186\/s13046-022-02318-0"},{"issue":"1","key":"8674_CR37","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1097\/SLA.0000000000003945","volume":"275","author":"R Kandimalla","year":"2022","unstructured":"Kandimalla R, Shimura T, Mallik S, et al. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Ann Surg. 2022;275(1):e229\u201337. https:\/\/doi.org\/10.1097\/SLA.0000000000003945.","journal-title":"Ann Surg"},{"issue":"6","key":"8674_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/biom13060877","volume":"13","author":"H Yang","year":"2023","unstructured":"Yang H, Liu Y, Chen L, et al. MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges? Biomolecules. 2023;13(6):877. https:\/\/doi.org\/10.3390\/biom13060877. Published 2023 May 23.","journal-title":"Biomolecules"},{"issue":"1","key":"8674_CR39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13046-021-02193-1","volume":"40","author":"R Cuciniello","year":"2021","unstructured":"Cuciniello R, Filosa S, Crispi S. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. J Exp Clin Cancer Res. 2021;40(1):383. https:\/\/doi.org\/10.1186\/s13046-021-02193-1. Published 2021 Dec 4.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08674-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:15:36Z","timestamp":1788794136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08674-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8674"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08674-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. The clinical trials involving human participants in this study were approved by the Ethics Committee of Guangxi Medical University Affiliated Tumor Hospital (approval number: KY2024308), and strictly complied with the Helsinki Declaration. All animal experiments were performed in accordance with relevant guidelines and regulations, and were approved by the Animal Ethics Committee of Guangxi Medical University Cancer Hospital (approval number: KY2024309).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1151"}}